Cronos Group Inc vs Keysight Technologies Inc — how do they compare? Cronos Group Inc trades at $3.23 (market cap $1.18B), while Keysight Technologies Inc trades at $380 (market cap $63.79B). The key difference: Keysight Technologies Inc is far larger — about 54.1× Cronos Group Inc's market cap, and Keysight Technologies Inc is trading nearer its 52-week high, Cronos Group Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Cronos Group Inc for 22 Days and Keysight Technologies Inc for 56 Days on average.
| CRON | KEYS | |
|---|---|---|
Market Cap | $1.18B | $63.79B |
Volume | 968,037 | 1,435,384 |
Sector | Health | Technology |
52-Week High | $3.55 | $387.90 |
52-Week Low | $2.30 | $159.49 |
Typical Hold Time | 22 Days | 56 Days |
Enterprise Value | $387.62M | $63.93B |
Signals from Pluang's Aura AI — not financial advice
CRON trades at $3.24, down 1.37% on the day, with a bearish technical signal and neutral oscillators. The company reported a net loss of $9.45M in 2025 despite revenue growth to $146.59M, but recent quarters show earnings beats. Analyst sentiment is mixed with 20% buy, 60% hold, and 20% sell ratings. Recent news highlights investor day events and international expansion efforts.
The outlook is cautious; profitability improvements and cash flow generation are key catalysts, but high valuation multiples and negative net cash flow pose risks. Regulatory developments in cannabis markets and execution on growth targets will be critical for stock performance.
Keysight Technologies (KEYS) trades at $381.49, down 1.65% on the day, amid strong fundamental performance with Q2 2026 EPS beating estimates at $3.07. The stock shows a bullish technical trend, trading near the pivot point of $380 with support at $377. Revenue for 2025 reached $5.38B, with net income of $850M, and the company is actively advancing in AI infrastructure and 6G testing, as highlighted in recent product launches and collaborations.
Outlook remains positive with a consensus price target of $416.63, representing a 9.2% upside, supported by accelerating earnings and strong AI demand. Risks include high valuation multiples, such as a P/E of 51.61, and supply constraints that may limit near-term revenue conversion despite surging orders.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Cronos Group, headquartered in Toronto, Canada cultivates and sells medicinal and recreational cannabis through its medicinal brand, Peace Naturals, and its two recreational brands, Cove and Spinach. Although it primarily operates in Canada, Cronos exports medical cannabis to Poland and Germany. In addition, it has entered joint ventures in Israel, Colombia, and Australia to drive further international cultivation and distribution growth. In the U.S. the company directly sells hemp-derived CBD and has an option to acquire 10.5% of U.S. multistate operator PharmaCann.
Read more on CRON →Keysight Technologies is a leader in the field of testing and measurement, helping electronics OEMs and suppliers alike bring products to market to fit industry standards and specifications. Keysight specializes in the communications market, but also supplies into the government, automotive, industrial, and semiconductor manufacturing markets. Keysight's solutions include testing tools, analytical software, and services. The firm's stated objective is to reduce time to market and improve efficiency at its more than 30,000 customers.
Read more on KEYS →